Johannes Mann
Friedrich-Alexander-Universität Erlangen-Nürnberg, KfH Kuratorium für Dialyse und Nierentransplantation, Munich General Hospital
Research areas: Medicine · Nephrology · Chronic Kidney Disease and Diabetes · Blood Pressure and Hypertension Studies · Diabetes Treatment and Management
About
Johannes F. E. Mann, M.D., is currently (since 1989) full Professor of Medicine at the Friedrich Alexander University of Erlangen, Germany and (since 2010) Senior International Scholar at Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
His previous assignments include Head, KfH Kidney Center, Munich, Germany; Director of Dept. of Nephrology, Munich General Hospitals; staff member and assistant Professor of Medicine, Dept. of Medicine, University of Heidelberg, Germany, and research fellowships in Pharmacology at the Universities of Montreal, Canada and of Heidelberg, Germany.
Professor Mann, a board-certified specialist in Internal Medicine, in Nephrology, in Intensive Care and in Pharmacology, was an officer of the German Societies of Medicine and of Nephrology, of the International Society of Nephrology and is on the editorial board of major journals of nephrology.
His scientific work includes about 300 original paper. His H-Index is 105 in 2025; his citations rank among the top 25 of European nephrologists. Some of his papers, published in Nature, NEJM, Lancet, JAMA and Ann Int Med, were cited more than 3000 times, total citations are close to 75,000 (2026).
The work of Professor Mann concerned initially the physiology of the renin-angiotensin system in experimental animals and later the role of this system for diseases of the kidney, the heart, the arteries, and for diabetes and its damages. From there, his interest moved to the treatment and prevention of progressive renal diseases, including diabetic and hypertensive kidney disease. The latter included planning, steering, adjudication and DSMB memberships in pivotal large outcome trials, namely AIPRI, HOPE, MICRO-HOPE, HOPE-TOO, HOPE-2, HOPE-3, ONTARGET, RENAL-ONTARGET, TRANSCEND, RENAL-TRANSCEND, ASCEND, DIABHYCAR, ORIGIN, LEADER, SONAR, SOUL, TIPS-3, FLOW, DAPA_CKD, DIALYZE, STABILZE, SOLOIST, SCORED, PRECISION, CONFIDENCE, AWAKE, CONCORDE, SYNCHRONIZE, TRIUMPF, FIND-CKD, PERIDOT, CARAT, BaxDuo ARCTIC, -PACIFIC, _PREVENT, AVENULAR, LIVERAGE, FIRST,
Employment
-
KfH Kuratorium für Dialyse und Nierentransplantation Medical director1993 - 2025
-
Munich General Hospital Chair, Dept. of Nephrology & Hypertension & Rheumatology1992 - 2015
-
Friedrich-Alexander-Universität Erlangen-Nürnberg Full professor1989 - Present
-
Friedrich-Alexander-Universität Erlangen-Nürnberg Vice chair, Dept. of Nephrology & Hypertension1989 - 1992
-
Universitätsklinikum Heidelberg Intern, nephrology fellow, assistant professor1980 - 1989
-
Montreal Clinical Research Institute senior fellow1978 - 1980
-
Heidelberg University fellow1976 - 1978
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (18)
- Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone Save
- Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265 Save
- Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial Save
- Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both Save
- Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial Save
- Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia Save
- Response to the letter to the editor entitled “Semaglutide and kidney function: direct kidney protection or an artifact?” Save
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials Save
- Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET) Save
- Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial Save
- Cardiorenal effects of dual blockade with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people with CKD: analysis of routinely collected data with emulation of a reference trial (ONTARGET) Save
- Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD Save
- Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes Save
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial Save
- Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD Save
- Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis Save
- Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial Save
- Dapagliflozin in Patients with Chronic Kidney Disease. Save